REVIEW article

Front. Cell Dev. Biol.

Sec. Cancer Cell Biology

Volume 13 - 2025 | doi: 10.3389/fcell.2025.1606530

This article is part of the Research TopicAdvances in Gastrointestinal CancersView all articles

The Role of SIRT1 in The Development of Gastrointestinal Tumors

Provisionally accepted
  • First Affiliated Hospital of Jilin University, Changchun, China

The final, formatted version of the article will be published soon.

Gastrointestinal tumors, including esophageal cancer (EC), gastric cancer (GC) and colorectal cancer (CRC) and, pose significant global health challenges due to their high morbidity and mortality rates. SIRT1, an NAD + -dependent deacetylase, plays diverse roles in physiological processes and has been implicated in cancer development.This review examines the dual roles of SIRT1 in gastrointestinal tumors. In EC, SIRT1 consistently promotes tumor progression, with high SIRT1 expression associated with advanced TNM stage, poor prognosis, lymph node metastasis, and inferior overall survival. In GC, SIRT1 similarly promotes tumor progression via autophagy and chemoresistance, but studies also highlight its potential anti-cancer effects through ferroptosis regulation. In CRC, SIRT1 is often overexpressed and promotes tumor progression through mechanisms involving p53 inhibition, activation of the Wnt/βcatenin pathway, and regulation of Epithelial-Mesenchymal Transition (EMT).However, conflicting evidence suggests SIRT1 can also act as a tumor suppressor by inhibiting β-catenin and nuclear factor-κB (NF-κB) signaling. The dual nature of SIRT1 underscores the need for context-specific understanding of its function. Future research should focus on elucidating SIRT1's mechanisms and developing personalized therapeutic strategies targeting SIRT1.

Keywords: SIRT1, colorectal cancer, gastric cancer, tumor progression, chemoresistance

Received: 05 Apr 2025; Accepted: 30 May 2025.

Copyright: © 2025 Zhang, Zhou, Zhai, Ma and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Sixi Zhang, First Affiliated Hospital of Jilin University, Changchun, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.